Oncology Drug Handling Near-Misses: Clinical Risks, Pathophysiology, and Guideline-Based Approaches

Abstract

Oncology drug handling is an intricate process with significant potential for near-miss incidents, posing risks to patient safety and healthcare personnel. This review critically examines the epidemiology, underlying mechanisms, risk factors, and clinical features of near-misses in oncology drug handling, while emphasizing diagnostic strategies, management, emerging advancements, and current guideline recommendations. The aim is to provide evidence-based, clinically actionable insights for healthcare professionals, supporting safer oncology practice and improved patient outcomes.

Introduction

The administration and handling of chemotherapeutic and targeted oncology agents carry inherent risks due to the cytotoxic, immunomodulatory, and complex pharmacological profiles of these drugs. Near-miss incidents—events that could have resulted in harm but were intercepted before reaching the patient—are critical learning opportunities for enhancing safety systems. Understanding the multifaceted aspects of oncology drug handling near-misses is essential for oncologists, pharmacists, nurses, and allied healthcare providers involved in cancer care delivery.

Epidemiology / Disease Burden

Near-miss reporting systems across oncology centers reveal a substantial burden of such events, with estimates ranging from 5% to 15% of all chemotherapy-related medication errors. The true incidence is believed to be underreported due to variable surveillance and a culture of under-recognition. High-volume cancer centers and outpatient infusion clinics are particularly susceptible, given the increasing complexity and frequency of multi-agent regimens. Notably, near-misses often involve high-alert agents such as anthracyclines, platinum compounds, and novel immunotherapies, amplifying the clinical significance of even intercepted errors.

Pathophysiology

The pathophysiological risk posed by oncology drug handling near-misses is rooted in the potent cytotoxicity of antineoplastic agents. Accidental exposure—whether via aerosolization, skin contact, or inadvertent administration—can result in acute and chronic toxicities, including myelosuppression, hypersensitivity reactions, secondary malignancies, and end-organ dysfunction. Precise knowledge of the mechanisms by which these drugs exert their effects, such as DNA intercalation, mitotic inhibition, or immune checkpoint blockade, underscores the necessity for impeccable handling protocols and rapid error interception strategies.

Risk Factors

Multiple contributory factors elevate the risk of near-misses in oncology drug handling. These include polypharmacy, look-alike/sound-alike drug nomenclature, complex dosing calculations adjusted for renal/hepatic function, insufficient staff training, and workflow interruptions. Institutional issues such as understaffing, inadequate double-check procedures, and absence of standardized compounding practices further compound risk. Patient-specific factors, such as frailty, comorbidities, and communication barriers, can also increase susceptibility to near-miss events.

Clinical Features

While near-misses by definition do not result in patient harm, their clinical features are often revealed through vigilant incident reporting and root cause analysis. The most prevalent near-misses involve errors in drug selection, dose calculation, compounding, labeling, and administration timing. Near-misses may also manifest as unauthorized preparation of hazardous drugs or accidental spillage, with potential for staff exposure leading to symptoms such as skin erythema, respiratory irritation, or, in extreme cases, systemic toxicity. Early recognition and reporting are essential for real-time mitigation and institutional learning.

Diagnosis

Diagnosis of a near-miss is reliant on robust detection systems, including electronic prescribing alerts, barcode verification, double-check protocols, and multidisciplinary huddles. Root cause analysis tools such as Failure Mode and Effects Analysis (FMEA) and the use of standardized incident reporting forms facilitate systematic identification and categorization. Regular audits and feedback mechanisms are critical for ongoing surveillance and continuous quality improvement in oncology drug handling processes.

Treatment & Management

Management of near-miss events in oncology drug handling prioritizes immediate risk containment and systematic review. Interventions include prompt notification of supervising clinicians, isolation and proper disposal of implicated drugs, decontamination procedures in case of exposure, and supportive care for affected staff or patients. Institutional responses should focus on root cause remediation, staff retraining, and policy review. Establishing a non-punitive culture that emphasizes learning and prevention is essential for sustained improvements in safety.

Recent Advances / Emerging Therapies

Technological innovations have markedly enhanced the interception of near-misses. Closed-system drug transfer devices (CSTDs), automated compounding robots, and advanced computerized physician order entry (CPOE) systems with integrated clinical decision support have demonstrated efficacy in reducing handling errors. Artificial intelligence-driven risk prediction models and real-time error surveillance platforms are emerging as promising tools for preemptive identification and mitigation of near-miss events. Additionally, ongoing research into less toxic oral and subcutaneous oncology therapies may reduce the frequency of hazardous drug handling.

Guideline Recommendations

Leading bodies such as the American Society of Clinical Oncology (ASCO), Oncology Nursing Society (ONS), and United States Pharmacopeia (USP <800>) have published comprehensive guidelines emphasizing the use of personal protective equipment (PPE), standardized compounding and administration protocols, mandatory double-checks, and continuous staff education. Reporting and root cause analysis of near-miss incidents are strongly encouraged to foster a culture of safety. Implementation of closed-system transfer devices and engineering controls is recommended to minimize occupational exposure, with regular audits to ensure compliance and effectiveness.

Conclusion

Oncology drug handling near-misses are prevalent, clinically significant events that necessitate rigorous preventive strategies, multidisciplinary vigilance, and adherence to evolving practice guidelines. By addressing underlying risk factors, implementing advanced technologies, and fostering a transparent, learning-oriented safety culture, healthcare professionals can substantially reduce the risk of harm to both patients and staff. Ongoing research and quality improvement initiatives remain pivotal for advancing the standard of oncology care and ensuring the safest possible therapeutic environment.